Literature DB >> 17145365

A structurally based approach to determine HLA compatibility at the humoral immune level.

Rene J Duquesnoy1.   

Abstract

HLAMatchmaker is a structurally based matching program. Each HLA antigen is viewed as a string of epitopes represented by short sequences (triplets) involving polymorphic amino acid residues in antibody-accessible positions. HLAMatchmaker determines which triplets are different between donor and recipient, and this algorithm is clinically useful in determining HLA mismatch acceptability. Triplets provide however an incomplete description of the HLA epitope repertoire and expanded criteria must be used including longer sequences and polymorphic residues in discontinuous positions. Such criteria should consider the structural basis of antibody-antigen interactions including contact areas and binding energy, the essence of antigenicity. This report describes the development of a structurally defined HLA epitope repertoire based on stereochemical modeling of crystallized complexes of antibodies and different protein antigens. This analysis considered also data in the literature about contributions of amino acid residues to antigen-antibody binding energy. The results have led to the concept that HLA antigens like other antigenic proteins have structural epitopes consisting of 15-22 residues that constitute the binding face with alloantibody. Each structural epitope has a functional epitope of about 2-5 residues that dominate the strength and specificity of binding with antibody. The remaining residues of a structural epitope provide supplementary interactions that increase the stability of the antigen-antibody complex. Each functional epitope has one or more non-self residues and the term "eplet" is used to describe polymorphic HLA residues within 3.0-3.5 A of a given sequence position on the molecular surface. Many eplets represent short linear sequences identical to those referred to as triplets but others have residues in discontinuous sequence positions that cluster together on the molecular surface. Serologically defined HLA determinants correspond well to eplets. The eplet version of HLAMatchmaker represents therefore a more complete repertoire of structurally defined HLA epitopes and provides a more detailed assessment of HLA compatibility.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17145365      PMCID: PMC2169290          DOI: 10.1016/j.humimm.2006.08.001

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  109 in total

1.  Three-dimensional structures of the free and antigen-bound Fab from monoclonal antilysozyme antibody HyHEL-63(,).

Authors:  Y Li; H Li; S J Smith-Gill; R A Mariuzza
Journal:  Biochemistry       Date:  2000-05-30       Impact factor: 3.162

Review 2.  Unraveling hot spots in binding interfaces: progress and challenges.

Authors:  Warren L DeLano
Journal:  Curr Opin Struct Biol       Date:  2002-02       Impact factor: 6.809

Review 3.  Reductionism and the search for structure-function relationships in antibody molecules.

Authors:  Marc H V Van Regenmortel
Journal:  J Mol Recognit       Date:  2002 Sep-Oct       Impact factor: 2.137

4.  Is the application of HLAMatchmaker relevant in kidney transplantation?

Authors:  Rene J Duquesnoy; Frans H J Claas
Journal:  Transplantation       Date:  2005-01-27       Impact factor: 4.939

5.  The number of amino acid residues mismatches correlates with flow cytometry crossmatching results in high PRA renal patients.

Authors:  A L Lobashevsky; R W Senkbeil; J L Shoaf; A K Stephenson; S B Skelton; R M Burke; M H Deierhoi; J M Thomas
Journal:  Hum Immunol       Date:  2002-05       Impact factor: 2.850

6.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. I. Description of the algorithm.

Authors:  René J Duquesnoy
Journal:  Hum Immunol       Date:  2002-05       Impact factor: 2.850

7.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. II. Verification of the algorithm and determination of the relative immunogenicity of amino acid triplet-defined epitopes.

Authors:  René J Duquesnoy; Marilyn Marrari
Journal:  Hum Immunol       Date:  2002-05       Impact factor: 2.850

8.  How do two unrelated antibodies, HyHEL-10 and F9.13.7, recognize the same epitope of hen egg-white lysozyme?

Authors:  Jaume Pons; Jennifer R Stratton; Jack F Kirsch
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

9.  Differences in electrostatic properties at antibody-antigen binding sites: implications for specificity and cross-reactivity.

Authors:  Neeti Sinha; Srinivasan Mohan; Claudia A Lipschultz; Sandra J Smith-Gill
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

10.  Dissection of binding interactions in the complex between the anti-lysozyme antibody HyHEL-63 and its antigen.

Authors:  Yili Li; Mariela Urrutia; Sandra J Smith-Gill; Roy A Mariuzza
Journal:  Biochemistry       Date:  2003-01-14       Impact factor: 3.162

View more
  57 in total

1.  HLAMatchmaker: a molecularly based algorithm for histocompatibility determination. V. Eplet matching for HLA-DR, HLA-DQ, and HLA-DP.

Authors:  Rene J Duquesnoy; Medhat Askar
Journal:  Hum Immunol       Date:  2006-10-30       Impact factor: 2.850

2.  HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment.

Authors:  Joseph Rimando; Michael Slade; John F DiPersio; Peter Westervelt; Feng Gao; Chang Liu; Rizwan Romee
Journal:  Blood Adv       Date:  2018-12-26

Review 3.  Immunological Monitoring in Beta Cell Replacement: Towards a Pathophysiology-Guided Implementation of Biomarkers.

Authors:  Fanny Buron; Sophie Reffet; Lionel Badet; Emmanuel Morelon; Olivier Thaunat
Journal:  Curr Diab Rep       Date:  2021-04-25       Impact factor: 4.810

4.  Class II Eplet Mismatch Modulates Tacrolimus Trough Levels Required to Prevent Donor-Specific Antibody Development.

Authors:  Chris Wiebe; David N Rush; Thomas E Nevins; Patricia E Birk; Tom Blydt-Hansen; Ian W Gibson; Aviva Goldberg; Julie Ho; Martin Karpinski; Denise Pochinco; Atul Sharma; Leroy Storsley; Arthur J Matas; Peter W Nickerson
Journal:  J Am Soc Nephrol       Date:  2017-07-20       Impact factor: 10.121

5.  The association between human leukocyte antigen eplet mismatches, de novo donor-specific antibodies, and the risk of acute rejection in pediatric kidney transplant recipients.

Authors:  Ankit Sharma; Anne Taverniti; Nicole Graf; Armando Teixeira-Pinto; Joshua R Lewis; Wai H Lim; Stephen I Alexander; Anne Durkan; Jonathan C Craig; Germaine Wong
Journal:  Pediatr Nephrol       Date:  2020-02-17       Impact factor: 3.714

6.  Structurally based epitope analysis of major histocompatibility complex class I-related chain A (MICA) antibody specificity patterns.

Authors:  Rene J Duquesnoy; Justin Mostecki; Jayasree Hariharan; Ivan Balazs
Journal:  Hum Immunol       Date:  2008-10-26       Impact factor: 2.850

7.  Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes.

Authors:  Rene J Duquesnoy; Yehia Awadalla; Jon Lomago; Larry Jelinek; Judy Howe; Dwayne Zern; Betty Hunter; Joan Martell; Alin Girnita; Adriana Zeevi
Journal:  Transpl Immunol       Date:  2007-10-30       Impact factor: 1.708

Review 8.  Optimal HLA matching in hematopoietic cell transplantation.

Authors:  Effie W Petersdorf
Journal:  Curr Opin Immunol       Date:  2008-08-08       Impact factor: 7.486

9.  Why can sensitization by an HLA-DR2 mismatch lead to antibodies that react also with HLA-DR1?

Authors:  Marilyn Marrari; Rene J Duquesnoy
Journal:  Hum Immunol       Date:  2009-03-09       Impact factor: 2.850

10.  HLA antibody testing: a tool to facilitate not to prevent organ transplantation.

Authors:  Frans H J Claas
Journal:  Int J Immunogenet       Date:  2008-08       Impact factor: 1.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.